Organisation
Department of Basic and Applied Medical Sciences
Department
Current researchers
31 - 40 of 71 results
- Bjorn Heyse (Member)
- Anke Kieckens (Member)
- Alain Labro (Member)
- Maxime Lammens (Member)
- Romain Lefebvre (Member)
- Luc Leybaert (Member)
- Alessio Lissoni (Member)
- Marieke Lobeau (Member)
- Cathérine Matthys (Member)
- Rania Matthys (Member)
Projects
31 - 40 of 80
- Peptide-based biopesticides for crop protectionFrom1 Apr 2022 → 31 Mar 2023Funding: IWT / VLAIO personal funding - innovation mandates
- NADPH OXIDASE 1 INHIBITION AS NEW THERAPEUTIC OPTION FOR HEPATOCELLULAR CARCINOMAFrom1 Jan 2022 → TodayFunding: Nonprofit institution or equivalents
- SCN9A mutations as a possible contributing factor to Primary DysautonomiaFrom1 Jan 2022 → 30 Apr 2023Funding: Foreign public sponsor
- Prediction of immunotherapy response and toxicity in melanoma, renal cell and lung cancer using transcriptome based systemic immune phenotyping.From1 Nov 2021 → TodayFunding: FWO fellowships
- The role of macrophages in electrical remodelling of hiPSC-cardiomyocytes: distinguishing the impact of inflammatory soup from direct macrophage-cardiomyocyte contactFrom1 Nov 2021 → 31 Oct 2023Funding: FWO fellowships
- Immune profiling and the role of monocyte/macrophage populations in primary sclerosing cholangitis and related ulcerative colitisFrom1 Nov 2021 → TodayFunding: FWO fellowships
- Immune profiling and the role of monocyte/macrophage populations in primary sclerosing cholangitis and related ulcerative colitis.From1 Oct 2021 → 31 Oct 2021Funding: BOF - doctoral mandates
- The role of Nav1.9 in the IBS-related symptomsFrom1 Oct 2021 → TodayFunding: FWO junior postdoctoral fellowship
- Innovative polymer scaffold for artificial meniscus replacement: from ‘zero-design’ to premium functional implantable device.From15 Jul 2021 → 30 Nov 2023Funding: IOF - technology validation in lab
- Regucyte : Bringing Regenerative Medicine to the ClinicFrom15 Apr 2021 → TodayFunding: IOF - technology validation in lab
Publications
1 - 10 of 1657
- Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma(2016)
Authors: Tijl Vermassen, M. Van de Walle, Sylvie Rottey
Pages: 12 - 18 - REACT expanded-access program in patients with metastatic renal cell carcinoma : real-world data from a European subanalysis(2015)
Authors: S Bracarda, Sylvie Rottey, A Bahl, C Eichelberg, B Mellado, L Mangel, A Cattaneo, A Panneerselvam, V Grunwald
Pages: 2893 - 2903 - Mobile health technology captures 'in-house' data on the outside : an assessment with pharmacological intervention(2019)Volume: 105
Authors: G Bhatia, Q Huang, T Crumley, C Walters, L Cluckers, I Heirman, L Mixson, Sylvie Rottey, M Cantor, C Benko, et al.
Pages: S73 - S73 - Glycosylation of urinary prostate proteins and its potential diagnostic applications(2017)
Authors: Tijl Vermassen
Pages: 126 - 128 - Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer(2020)Volume: 8
Authors: Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey, Nabil Adra, Mark Salvati, Shirley Poon, et al.
Pages: A207 - A208 - Cytoreductive nephrectomy and exposure to sunitinib : a post hoc analysis of the immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME) trial(2022)
Authors: Yasmin AbuU+2010Ghanem, Johannes V. Thienen, Christian Blank, Maureen J. B. Aarts, Michael Jewett, Igle Jan Jong, JeanU+2010Baptiste Lattouf, Harm H. E. Melick, Lori Wood, Peter Mulders, et al.
Pages: 68 - 75 - Nephrotoxicity of anticancer drugs: an underestimated problem?(2011)
Authors: VIBEKE KRUSE, Sylvie Rottey
Pages: 337 - 345 - Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial(2013)
Authors: Jan B Vermorken, Jan Stoelmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Skladowski, Makoto Tahara, et al.
Pages: 697 - 710 - A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors(2020)Volume: 80
Authors: Juanita S. Lopez, Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schuler, Matthew Hellmann, Ani Balmanoukian, Luc Dirix, Michael Gordon, Ryan Sullivan, et al.
Number of pages: 1 - Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : the SURTIME randomized clinical trial(2019)
Authors: Axel Bex, Peter Mulders, Michael Jewett, John Wagstaff, Johannes V van Thienen, Christian U Blank, Roland van Velthoven, Maria del Pilar Laguna, Lori Wood, Harm HE van Melick, et al.
Pages: 164 - 170